Replicate Bioscience is extending its low-dose self-replicating RNA platform into tuberculosis, but immunological complexity, late-stage competition and global affordability create a demanding development path.
Denali Therapeutics is converting AVLAYAH’s regulatory reward into non-dilutive capital for its blood-brain barrier pipeline, but clinical and commercial risks remain.
Staged bilateral focused ultrasound reduced Parkinson’s motor complications without implanted hardware, but persistent speech, gait and balance effects narrow the patients most likely to benefit.
Autonomous Medical Devices Incorporated has secured FDA clearance and a CLIA waiver for a four-virus PCR panel, but speed alone may not guarantee widespread adoption.
Updated 9MW2821 data support Nectin-4 as a target in cervical cancer, but Mabwell must prove that early response and survival signals outperform established ADC and immunotherapy options.
Early ixotatug vedotin and bevacizumab data suggest activity in Claudin 6-positive ovarian cancer, but the small uncontrolled study cannot yet separate ADC efficacy from combination effects.
KIT2014 cleared its first human safety study with no measurable systemic exposure, but Kither Biotech must now prove that its peptide can improve lung function and inflammation in patients.
The ENERGY trial strengthens the regulatory case for nipocalimab in warm autoimmune hemolytic anemia, but modest response rates and long-term IgG suppression remain important questions.
Frontline On Demand Plasma could bring plasma transfusion closer to ambulances, disaster zones and military front lines, but clinical and regulatory hurdles remain.
cAMPfield Therapeutics is backing prifemilast as a better-tolerated oral PDE4 inhibitor for inflammatory bowel disease, but mid-stage trials must prove that selectivity translates into durable remission.